...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy and asthma proceedings >Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma.
【24h】

Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma.

机译：与过敏性鼻炎和哮喘患者的对症药物治疗相比，变应原免疫疗法的药物经济学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Only a few studies analyzed the pharmacoeconomics of allergen immunotherapy compared with drug treatment in subjects with allergic rhinitis and asthma. This study was aimed at evaluating whether allergen immunotherapy has an economic advantage on standard antiallergic drugs in patients with pollen-induced rhinitis and asthma. Thirty patients with rhinitis and asthma caused by Parietaria pollen were included in the study, 20 (11 men and 9 women; mean age, 35.45 +/- 10.45 years) were treated with subcutaneous immunotherapy by a Parietaria judaica extract (Alustal, Stallergenes, Antony, France) by a conventional build-up schedule in 12 weeks and a maintenance treatment every 4 weeks for 3 years, and 10 (6 men and 4 women; mean age, 31.90 +/- 10.97 years) were treated with antiallergic drugs. Each patient was evaluated before starting the treatment and annually for 6 years in the pollen period of Parietaria by means of nose, eyes, and lung symptom scores, along with drug consumption registered in diary cards. In other specifically designated cards general practitioner's or specialist's visits, the number of desensitizing injections and the number of boxes of antiallergic drugs were registered. A significant difference in favor of immunotherapy plus drug treatment versus drug treatment alone was observed, reaching a cost reduction of approximately 15% the second year and 48% the third year, with a highly statistical significance that was maintained up to the sixth year, i.e., 3 years after stopping immunotherapy, when an 80% reduction was found. The net saving for each patient at the final evaluation corresponded to euros 623 (dollars 830)/year. These findings confirm some previous observations in studies from Germany and the United States that subcutaneous immunotherapy has significant economic advantages over antiallergic drug treatment in the long term.
机译：只有少数研究分析了过敏性鼻炎和哮喘患者与药物治疗相比的变应原免疫疗法的药物经济学。这项研究旨在评估在花粉诱发的鼻炎和哮喘患者中，过敏原免疫疗法是否比标准抗过敏药物具有经济优势。该研究纳入了30例由Parietaria花粉引起的鼻炎和哮喘患者，其中20例（男11例，女9例;平均年龄35.45 +/- 10.45岁）通过Parietaria judaica提取物（Alustal，Stallergenes，Antony）进行了皮下免疫治疗。 （法国）按照常规疗程安排，在12周内进行治疗，每4周进行一次维持治疗，持续3年，并用抗过敏药治疗10例（6名男性和4名女性;平均年龄为31.90 +/- 10.97岁）。在开始治疗之前，每年对每位患者进行一次评估，在Parietaria的花粉期中，通过鼻子，眼睛和肺部症状评分以及在日记卡中记录的药物消耗情况，每年评估6年。在其他特别指定的卡中，全科医生或专科医生的访问中，记录了脱敏注射剂的数量和抗过敏药的盒数。观察到在免疫疗法加药物治疗与单独药物治疗之间存在显着差异，第二年的费用降低了约15％，第三年的费用降低了48％，在第6年即第6年一直保持着高度的统计意义。 ，在停止免疫治疗3年后，发现减少了80％。在最终评估中，每位患者的净节省额相当于每年623欧元（830美元）。这些发现证实了德国和美国之前的一些研究发现，从长期来看，皮下免疫疗法比抗过敏药物疗法具有明显的经济优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号